Live Breaking News & Updates on சமூகம் க்கு ஆராய்ச்சி ஆன் நிகோடின்

Stay updated with breaking news from சமூகம் க்கு ஆராய்ச்சி ஆன் நிகோடின். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NIH awards Marshall University professor $1.8 million for nicotine addiction research


 E-Mail
IMAGE: Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a $1.86 million Research Project Grant (R01).
view more 
Credit: Marshall University Joan C. Edwards School of Medicine
HUNTINGTON, W.Va. - Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health (NIH).
Henderson was awarded the $1.86 million five-year grant (R01DA050717) from the National Institute on Drug Abuse to study the neurobiological and neurophysiological changes that occur due to vaping nicotine in flavored products. Henderson s research team is working to better understand how electronic nicotine delivery systems, or vaping, alter neurobiology to trigger nicotine addic ....

West Virginia , United States , West Virginians , Josephi Shapiro , Brandonj Henderson , Centers For Disease , Yale University , National Institute On Drug Abuse , Joanc Edwards School Of Medicine , National Institutes Of Health , Ohio State University , California Institute Of Technology , Society For Research On Nicotine , Research Project Grant , Science Network , Marshall University Joan , National Institutes , National Institute , Drug Abuse , Disease Control , California Institute , Basic Science Network , மேற்கு வர்ஜீனியா , ஒன்றுபட்டது மாநிலங்களில் , மையங்கள் க்கு நோய் , யேல் பல்கலைக்கழகம் ,

Achieve Life Sciences, Inc.: Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update


(2)
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program.
Recent Events & Highlights
Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States
Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting on February 24, 2021 ....

United States , British Columbia , Jason Wong , John Bencich , Us Department Of Health , Human Services , World Health Organization , Exchange Commission , Society For Research On Nicotine , Health Consequences Of Smoking , Life Sciences Inc , Achieve Life Sciences , Annual Meeting , Chief Executive Officer , Highlighting Smoker Dissatisfaction , Available Treatments Presented , Cigarette Users Behavior , Quitting Intentions Presented , Private Securities Litigation Reform Act , Annual Reports , Quarterly Reports , Global Tobacco Epidemic , Health Consequences , Surgeon General , ஒன்றுபட்டது மாநிலங்களில் , பிரிட்டிஷ் கொலம்பியா ,